Clinical Trials on Extremely Low Birth Weight Infants in South Africa

Total 259 results

Horizon Pharma USA, Inc.
Forest Laboratories

Completed

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (TIS)

Cystic Fibrosis

United States, Ireland, United Kingdom, France, Germany, Israel
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, United Kingdom, New Zealand, Israel, Australia, Ireland, Germany, Sweden, Czechia, Portugal, Hungary
Proteostasis Therapeutics, Inc.

Completed

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

Cystic Fibrosis | Healthy Volunteer

United States, Canada, Denmark, Germany, Sweden
Tenax Therapeutics, Inc.

Active, not recruiting

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Heart Failure With Normal Ejection Fraction | Hypertension Pulmonary Secondary Heart Failure | Right Sided Heart Failure With Normal Ejection Fraction

United States
T. John Winhusen, PhD
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Active, not recruiting

Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs)

Pregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Drug Abuse in Pregnancy | Neonatal Opioid Withdrawal Syndrome

United States
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Netherton Syndrome

Belgium, United Kingdom, Australia, Germany, China, Malaysia, United States, Japan, France, Israel, Bulgaria, Italy, Switzerland, Austria, Netherlands, Portugal
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, France, Spain, Belgium, Canada, Austria, Australia, Germany, United Kingdom, Denmark
Genentech, Inc.

Terminated

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, France, Germany
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa (AIR-CF2)

Cystic Fibrosis

United States
Amalia Magaret
University of Texas; Cystic Fibrosis Foundation; National Jewish Health

Recruiting

Prospective Study of Pregnancy in Women With Cystic Fibrosis (MAYFLOWERS)

Pregnancy Related | Cystic Fibrosis

United States
Anthera Pharmaceuticals

Completed

Open-Label Phase III Long-Term Safety Trial of Liprotamase (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
T. John Winhusen, PhD
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Active, not recruiting

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (MOMs-CMA)

Pregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Drug Abuse in Pregnancy | Neonatal Opioid Withdrawal Syndrome

United States
Massachusetts General Hospital

Completed

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery (ASTER)

Sepsis | Critical Illness | Respiratory Failure | Acute Respiratory Distress Syndrome

United States
Horizon Pharma USA, Inc.

Completed

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Cystic Fibrosis (CF)

Germany, United States, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

United States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
Respirion Pharmaceuticals Pty Ltd

Recruiting

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Pseudomonas Aeruginosa | Cystic Fibrosis Lung | Respiratory Infections, Recurrent, Chronic

United States, Australia
AbbVie
VIVUS LLC; Cystic Fibrosis Foundation; Digestive Care, Inc.; Nestle Health Science

Terminated

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Fibrosing Colonopathy

United States
T. John Winhusen, PhD
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Recruiting

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (MOMs-INO)

Pregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Neonatal Opiate Withdrawal Syndrome | Drug Abuse in Pregnancy

United States
AbbVie

Completed

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

Cystic Fibrosis

United States, Belgium, Canada, Czechia, France, Hungary, Netherlands, New Zealand, Poland, Slovakia, United Kingdom, Serbia
Aceragen

Withdrawn

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations (REPRIEVE)

Cystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation

United States
Novartis Pharmaceuticals

Completed

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Pulmonary Infections | Pseudomonas Aeruginosa in Cystic Fibrosis

United States, Italy, Germany, France, Australia, Canada, Spain, Hungary, Mexico, Argentina
Celtaxsys, Inc.

Completed

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

Cystic Fibrosis

United States, United Kingdom, Canada, Belgium, France, Germany, Italy
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study (SIMPLIFY-DN)

Cystic Fibrosis

United States
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study (SIMPLIFY-HS)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)

Cystic Fibrosis

United States
Novartis

Terminated

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects (EVOLVE)

Cystic Fibrosis

United States, Argentina, Brazil, Bulgaria, Canada, Chile, Lithuania, Mexico
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Gilead Sciences
Cystic Fibrosis Foundation

Completed

Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients (AIR-CF5)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Switzerland, Canada, Denmark, Poland
Chris Goss
Medical University of South Carolina; University of Washington; Cystic Fibrosis... and other collaborators

Completed

Standardized Treatment of Pulmonary Exacerbations II (STOP2)

Pulmonary Cystic Fibrosis

United States, Canada
Mylan Inc.
Cystic Fibrosis Foundation

Completed

Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

Pseudomonas Aeruginosa in Cystic Fibrosis

United States
Novartis Pharmaceuticals

Completed

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis (EAGER)

Cystic Fibrosis

United States, Germany, United Kingdom, Colombia, Spain, France, Netherlands, Israel, Canada, Italy, Chile, Australia, Hungary, Mexico
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
Gilead Sciences
Salus Pharma, Inc.

Completed

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

Cystic Fibrosis | Pseudomonas Aeruginosa | Lung Infection | CF

United States
Gilead Sciences
Covance; ClinPhone, Inc.; Chiltern International Inc.

Completed

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Cystic Fibrosis

Belgium, France, Germany, Italy, Netherlands, Spain, United States, Ireland, United Kingdom, Portugal, Austria, Denmark, Switzerland
Chris Goss
Medical University of South Carolina; University of Washington; Cystic Fibrosis...

Recruiting

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study (STOP360AG)

Cystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation

United States, Canada
Alexion Pharmaceuticals

Terminated

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

Pneumonia, Viral | Acute Respiratory Distress Syndrome | Acute Lung Injury | COVID-19 Severe Pneumonia

United States, Spain, United Kingdom, France, Japan
Armata Pharmaceuticals, Inc.
Cystic Fibrosis Foundation

Completed

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis (SWARM-Pa)

Cystic Fibrosis | Pseudomonas Aeruginosa | Lung Infection | Pseudomonas | Lung Infection Pseudomonal

United States
BiomX, Inc.

Active, not recruiting

Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

Cystic Fibrosis | Chronic Pseudomonas Aeruginosa Infection

United States, Israel, Spain, Czechia, Netherlands
Bonnie Ramsey
National Heart, Lung, and Blood Institute (NHLBI)

Completed

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis (OPTIMIZE)

Cystic Fibrosis

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa (AIR-CF4)

Cystic Fibrosis | Pseudomonas Aeruginosa | Lung Infection

United States, Australia, Canada
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

Cystic Fibrosis | Burkholderia Infections

United States, Canada
Gilead Sciences

Completed

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF (AZLI CAT)

Cystic Fibrosis

United States
University of Washington, the Collaborative Health...
Cystic Fibrosis Foundation

Recruiting

Colorectal Cancer Screening in Cystic Fibrosis (NICE-CF)

Colorectal Cancer | Adenoma | Cystic Fibrosis

United States
UK Kidney Association

Recruiting

National Registry of Rare Kidney Diseases (RaDaR)

Vasculitis | AL Amyloidosis | Tuberous Sclerosis | Fabry Disease | Cystinuria | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Bartter Syndrome | Pure Red Cell Aplasia | Membranous Nephropathy | Atypical Hemolytic Uremic Syndrome | Autosomal Dominant Polycystic Kidney Disease | Cystinosis | Nephronophthisis | BK Nephropathy and other conditions

United Kingdom
Gilead Sciences

Terminated

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria (ALPINE 2)

Cystic Fibrosis | Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization

United States, Spain, United Kingdom, Denmark, Belgium, France, Italy, Germany, Israel, Netherlands, Austria, Greece
Gilead Sciences

Approved for marketing

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

Cystic Fibrosis | Pseudomonas Aeruginosa Airway Infection

United States, Puerto Rico

Clinical Trials on Extremely Low Birth Weight Infants in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations